UK Evidence and Guidance Ozempic (semaglutide) is a GLP-1 receptor agonist licensed in the UK for type 2 diabetes management, not for treating ovarian cysts directly
In these studies, for many individuals who have a BMI under 27 but who still experienced metabolic slowdown, microdosing seemed to provide a way to intervene early rather than waiting for things to become a diagnosable condition
estimates suggest it impacts between 48 million couples and 186 million individuals globally
Chacko RT, Ventura J, Zhuang J, Thayumanavan S
Extreme/rapid weight loss may result in nutritional deficiencies that lead to hair loss, anemia, weak bones or increased risk of infection
Even short-term treatment teaches your body new eating behaviors, resets your relationship with food, and creates metabolic adaptations that persist longer than the medication itself